Journal article · 2026
Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia
Clinical Pharmacology & Therapeutics, 119(5), 1298–1306 · Published 21 January 2026 · DOI 10.1002/cpt.70170
In brief
“Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia” is a 2026 journal article by Chin Hang Yiu and 2 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 9 citations as of 17 November 2026, which puts it in the top 2% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 9
- Most cited in
- 2026 (9)
- Field-weighted impact
- 21.25
- References
- 46
- Authors
- 3
Abstract
Lung cancer remains the leading cause of cancer-related mortality globally. While immune checkpoint inhibitors (ICIs) are the standard of care for metastatic non-small cell lung cancer (NSCLC), real-world data from Australia are limited. We conducted a population-based cohort study using national Pharmaceutical Benefits Scheme and National Death Index data, accessed via the Australian Bureau of… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Yiu, C. H., Clarke, S. J., & Lu, C. Y. (2026). Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia. Clinical Pharmacology & Therapeutics, 119(5), 1298–1306. https://doi.org/10.1002/cpt.70170
MLA 9
Yiu, Chin Hang, et al. “Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia.” Clinical Pharmacology & Therapeutics, vol. 119, no. 5, 2026, pp. 1298–1306. https://doi.org/10.1002/cpt.70170.
Chicago
Yiu, Chin Hang, Stephen John Clarke, and Christine Y. Lu. 2026. “Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia.” Clinical Pharmacology & Therapeutics 119 (5): 1298–1306. https://doi.org/10.1002/cpt.70170.
Harvard
Yiu, C. H., Clarke, S. J. and Lu, C. Y. (2026) ‘Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia’, Clinical Pharmacology & Therapeutics, 119(5), pp. 1298–1306. doi:10.1002/cpt.70170.
IEEE
C. H. Yiu, S. J. Clarke, and C. Y. Lu, “Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia,” Clinical Pharmacology & Therapeutics, vol. 119, no. 5, pp. 1298–1306, 2026, doi: 10.1002/cpt.70170.
BibTeX
@article{yiu2026real,
title = {{Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia}},
author = {Yiu, Chin Hang and Clarke, Stephen John and Lu, Christine Y.},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2026},
volume = {119},
number = {5},
pages = {1298--1306},
doi = {10.1002/cpt.70170},
url = {https://doi.org/10.1002/cpt.70170}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- pembrolizumab
- metastatic non-small cell lung cancer
- immune checkpoint inhibitors
- overall survival
- time to treatment discontinuation
- immune-related adverse events
- corticosteroid use
- levothyroxine
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Yiu, C. H., Clarke, S. J., & Lu, C. Y. (2026). Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia. Clinical Pharmacology & Therapeutics, 119(5), 1298–1306. https://doi.org/10.1002/cpt.70170
How many times has this paper been cited?
9 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Chin Hang Yiu, Stephen John Clarke, Christine Y. Lu.
What is the DOI of this paper?
10.1002/cpt.70170, permanently at https://doi.org/10.1002/cpt.70170. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.